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Conclusions: To our knowledge, this is the first paper 
addressing patient-reported acute GI and GU toxicity data 
from large prospective studies. We identified clinically 
relevant reductions in acute GI and GU toxicity for patients 
treated with IG-IMRT compared to 3D-CRT. This is the result 
of significantly lower doses to OARs, achieved by improved 
techniques and tighter margins. Since delivered dose to OARs 
as well as acute toxicity itself are known predictors of late 
toxicity, we expect this will eventually translate in lower late 
toxicity levels.  
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Purpose/Objective: According to European and American 
guidelines, treatment options after radical prostatectomy are 
adjuvant radiotherapy or early salvage radiotherapy (RT). In 
both cases, only prostate bed irradiation is recommended 
because any remaining tumor or local recurrence are most 
frequently located at this site. Recurrence in other sites can 
therefore be overlooked. In this study, we aimed to evaluate 
the incidence and location of visible recurrence on pelvic 
multiparametric MR (mpMR), to define the radiological 
criteria of local recurrence and lymph node spread after 
radical prostatectomy, and to determine the association of 
clinical and pathologic variables with imaging results. 
Materials and Methods: We retrospectively reviewed the 
clinical records and mpMR studies of 70 patients with PSA 
recurrence after radical prostatectomy. To investigate any 
association between clinical and pathological variables with 
imaging results, we recorded initial PSA, pT stage, 
pathological Gleason score, presence and location of 
extracapsular extension, vesicle involvement, margin status, 
number of positive margins, postoperative PSA, PSA at the 
time of MRI, PSA doubling time and open versus laparoscopy 
or robotic prostatectomy. Statistical analysis was performed 
using T-test and univariate and multivariate studies. 
MR protocol included T2 weighted TSE sequences, diffusion-
weighted sequences, calculation of apparent diffusion 
coefficient values, and dynamic contrast-enhanced MR with 
time curves generated from regions of interest. 
Results: mpMR was positive in 33/70 patients. We found no 
statistically significant differences between patients with 
positive or negative mpMR studies for any variables. Local 
recurrence occurred in 27 patients: perianastomotic (19), 
periurethral (1), right posterior to the bladder (3), left 
posterior to the bladder (1), right seminal vesicle bed (1), 
left seminal vesicle bed (1), and penile bulb (1). mpMR 
detected positive lymph nodes in 7 patients (14 
regions)(10%): right external iliac (5), left external iliac (4), 
right common iliac (2), left internal iliac (1), right obturator 
(1) ,and left obturator (1). 
Lower PSA doubling time was associated with positive lymph 
nodes (5.83 vs 17.35 months (p=0.05). Lymph node and local 
recurrence showed the same functional parameters in mpMR. 
Conclusions: Nearly half the patients with PSA-recurrence 
after radical prostatectomy had visible disease in mpMR. 
Incidence of positive lymph nodes should be considered when 
planning adjuvant or salvage radiotherapy. We recommend 
mpMR-guided RT rather than blind salvage RT.  
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Purpose/Objective: A subset of patients experience a PSA 
recurrence (rPSA) following radical prostatectomy. 
Radiotherapy can salvage those patients, provided that all 
disease is encompassed within the planning target volume 
(PTV) and a sufficient radiation dose is delivered. We 
hypothesized that these requirements can be achieved more 
adequately with MRI-guided radiation treatment planning. 
Materials and Methods: From January 2009 to April 2014, 238 
patients with rPSA were referred to our department for 
salvage radiotherapy. According to protocol, patients 
received a planning CT without IV contrast as well as a 
planning MRI in treatment position. MRI consisted of T1-, T2-, 
and diffusion-weighted (with an apparent diffusion 
coefficient (ADC) map) sequences. Dose to the prostate bed 
was 66.0 Gy in 33 fractions for all patients, delivered through 
intensity-modulated radiotherapy (IMRT). All MRI scans were 
reviewed by an experienced uro-radiologist. 
Results: Patients with a rPSA ≥ 5.0 µg/L or proven local 
recurrence were excluded from this analysis (n = 16). Of 222 
evaluable patients, 183 patients received both a planning CT 
and MRI while 39 patients only received a planning CT for 
various reasons. Patients were referred a mean 33.2 months 
(range: 6 – 161 months) after radical prostatectomy for a pT1 
(n = 1), pT2 (n = 108), pT3 (n = 68), or pT4 (n = 1) prostate 
adenocarcinoma (see Table). Median rPSA value at time of 
